CagriSema (Cagrilintide + Semaglutide) for Fat Loss
Investigational once-weekly fixed combination of the amylin analog cagrilintide and the GLP-1 agonist semaglutide, studied in the Phase 3 REDEFINE program for weight management.
Why CagriSema (Cagrilintide + Semaglutide) for fat loss?
According to PubMed, REDEFINE 1 (a 68-week Phase 3a trial, NCT05567796) reported an estimated mean body-weight change of -20.4% with cagrilintide-semaglutide versus -3.0% with placebo, with gastrointestinal adverse events in about 80% of the combination group, mostly transient (Garvey WT et al., N Engl J Med 2025). The earlier Phase 1b trial characterized the once-weekly pharmacokinetics supporting weekly dosing (Enebo LB et al., Lancet 2021). The combination is investigational and not yet approved.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. CagriSema (Cagrilintide + Semaglutide) fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Substantial weight loss in Phase 3 trials (about 20% at week 68 in REDEFINE 1)
- Greater weight loss than either component alone in the pivotal trial
Reference dosing by bodyweight
Anchored to the most-cited research dose (4000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 2493–3373 mcg |
| 60–75 kg / 132–165 lb | 3060–4140 mcg |
| 75–90 kg / 165–198 lb | 3740–5060 mcg |
| 90–105 kg / 198–231 lb | 4420–5980 mcg |
| >105 kg / >231 lb | 5100–6900 mcg |
Side effects to weigh against fat loss benefit
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain (mostly transient, mild to moderate)
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.